Retrospective Study
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Sep 6, 2020; 8(17): 3679-3690
Published online Sep 6, 2020. doi: 10.12998/wjcc.v8.i17.3679
Incidental anal 18fluorodeoxyglucose uptake: Should we further examine the patient?
Anne-Sophie Moussaddaq, Charlène Brochard, Xavier Palard-Novello, Etienne Garin, Timothée Wallenhorst, Eric Le Balc’h, Alexandre Merlini L’heritier, Thomas Grainville, Laurent Siproudhis, Astrid Lièvre
Anne-Sophie Moussaddaq, Charlène Brochard, Timothée Wallenhorst, Eric Le Balc’h, Alexandre Merlini L’heritier, Thomas Grainville, Laurent Siproudhis, Astrid Lièvre, Department of Gastroenterology, University Hospital of Rennes, Pontchaillou, Rennes 35000, France
Charlène Brochard, Laurent Siproudhis, Inphy CIC 1414 University Hospital of Rennes, Pontchaillou, Rennes 35000, France
Xavier Palard-Novello, Etienne Garin, Department of Nuclear Medicine, Cancer Institute Eugène Marquis, Rennes 35000, France
Etienne Garin, Laboratoire Traitement du Signal et de l'Image-UMR1099, University of Rennes, Inserm, Rennes 35000, France
Author contributions: Moussaddaq AS, Brochard C and Lièvre AM designed research; Moussaddaq AS, Brochard C, Palard-Novello X, Garin E, Wallenhorst, T, Le Balch E, Merlini L’Héritier A, Grainville T and Siproudhis L performed research; Moussaddaq AS, Brochard C, Palard-Novello X and Siproudhis L contributed analytic tools; Moussaddaq AS, Brochard C and Lièvre A analyzed data; Moussaddaq AS, Brochard C and Lièvre A wrote the paper.
Institutional review board statement: This study was reviewed and approved by the Hospital Ethics Committee of Rennes (n° 19.38) on April 4, 2019.
Informed consent statement: Patients were informed and did not express their opposition to participate in the study.
Conflict-of-interest statement: Charlène Brochard received lecture fees from Ipsen. Laurent Siproudhis received lecture fees from Abbvie, Ferring and MSD. Laurent Siproudhis received consultant fees from Takeda and Ferring. Others have no conflicts of interest.
Data sharing statement: Not applicable.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Charlène Brochard, MD, PhD, Doctor, Department of Gastroenterology, University Hospital of Rennes, Pontchaillou, 2 rue Henri Le Guillou, Rennes 35000, France. charlene.brochard@chu-rennes.fr
Received: January 3, 2020
Peer-review started: January 3, 2020
First decision: January 18, 2020
Revised: May 15, 2020
Accepted: August 1, 2020
Article in press: August 1, 2020
Published online: September 6, 2020
Processing time: 244 Days and 14.9 Hours
Core Tip

Core tip: This is a retrospective study to assess the rate and aetiologies of incidental anal 18F-fluorodeoxyglucose (18FDG) uptake and to evaluate the correlation between 18FDG positron-emission tomography/computed tomography parameters and the diagnosis of an anorectal disease. Incidental anal 18FDG uptake is rare, but a reliable anorectal diagnosis is commonly obtained when an anorectal examination is performed. The diagnosis of an anorectal disease induces treatment in more than one-third of the patients. These data should encourage practitioners to explore incidental anal 18FDG uptake systematically.